CytomX Therapeutics CTMX Continuing operations (in dollars per share)
Continuing operations (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's continuing operations (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's continuing operations (in dollars per share)?
- CytomX Therapeutics (CTMX) reported continuing operations (in dollars per share) of -$0.1 in Q1 2026.
- How has CytomX Therapeutics's continuing operations (in dollars per share) changed year-over-year?
- CytomX Therapeutics's continuing operations (in dollars per share) decreased by 137.0% year-over-year, from $0.27 to -$0.1.
- What is the long-term trend for CytomX Therapeutics's continuing operations (in dollars per share)?
- Over 3 years (2021 to 2025), CytomX Therapeutics's continuing operations (in dollars per share) has grown at a -71.9% compound annual growth rate (CAGR), from -$1.8 to -$0.04.